drugset / Trial / NCT00244452

A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis

NCT00244452

Phase 2 Completed Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Identify effective doses of cetrorelix SR in the treatment of symptoms of endometriosis, describe dose effect relationship and duration of symptom relief

Timeline

Start
2005-11
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetrorelix Other / unclassified

Indications